Envoy Medical Completes Pivotal Trial Enrollment, Reports Positive Early Data, and Secures $30M Capital
COCH sits 79% above its 52-week low of $0.363 on light trading volume (0.2× avg).
Summary
Envoy Medical announced the completion of enrollment in its pivotal clinical trial for the Acclaim cochlear implant and reported promising early clinical data, alongside a strengthened cash position from a recent $30 million capital raise.
Key Events · Product Development and Regulatory · COCH
-
Pivotal Trial Enrollment Completed
Envoy Medical successfully completed enrollment of 56 patients in its U.S. pivotal clinical trial for the Acclaim® cochlear implant on March 11, 2026, a critical step towards FDA Premarket Approval (PMA).
-
Positive Early Clinical Data Reported
Interim six-month data from the first 10 patients showed no serious adverse events and significant improvement in word recognition scores (from 15.2% to 39.2%), along with improvements in quality-of-life and tinnitus scores.
-
Strengthened Cash Position
The company reported a cash balance of approximately $25.25 million as of March 31, 2026, a substantial increase from $3.74 million at year-end 2025, following a $30 million capital raise.
-
Advancing Towards Commercialization
All 56 pivotal trial patients have been activated, and the first three patients have completed their 12-month endpoint visits, keeping the company on track for PMA submission.
Analysis · COCH · Industrial Applications And Services
This filing is critical as Envoy Medical, a company previously facing a 'going concern' warning, has achieved major milestones. The completion of enrollment in its pivotal clinical trial for the Acclaim cochlear implant and the presentation of positive interim 6-month data significantly de-risk its path to FDA approval and potential commercialization. Furthermore, the $30 million capital raise has substantially improved its cash position to $25.25 million, providing crucial runway to fund operations and advance the clinical program. This combination of clinical progress and financial stability is a strong positive for the company's future.
At the time of this filing, COCH was trading at $0.65 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $49.6M. The 52-week trading range was $0.36 to $1.91. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.